Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), ...

In common with Novo Nordisk’s semaglutide-based diabetes and obesity therapies – respectively Ozempic and Wegovy – Lilly has faced burgeoning demand for its therapies, despite which is ...

Novo Nordisk's STEP trial programme for once-weekly GLP-1 agonist Wegovy (semaglutide) revealed a reduction in body weight of around 12%, suggesting greater potency for Lilly's dual-acting drug ...

Lilly offers weight-loss drugs in vials at a ... February 24, 2025 Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list Drug compounders sued the U.S. Food and Drug ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out how Lilly could perform through the end of the decade, and decide whether ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Lone Pine Capital, established in 1997 by Stephen Mandel, is a leading hedge ...